Eman Hassan

Dr. Eman Hassan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
AAAli Abdelhameed
Ali Abdelhameed
ABAhmed H. Bakheit
Ahmed H. Bakheit
HAHaitham K. AlRabiah
Haitham K. AlRabiah
EHEman Hassan
Eman Hassan
FAFahad M. Almutairi
Fahad M. Almutairi

1 November 2018 in Journal of Luminescence
Verified
Journal Article
Closed access
AAAmer M. Alanazi
Amer M. Alanazi
AAAli Abdelhameed
Ali Abdelhameed
ABAhmed H. Bakheit
Ahmed H. Bakheit
EHEman Hassan
Eman Hassan
MAMaha S. Almutairi
Maha S. Almutairi
MAMohamed I. Attia
Mohamed I. Attia

1 April 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
AAAli Abdelhameed
Ali Abdelhameed
AAAmer M. Alanazi
Amer M. Alanazi
ABAhmed H. Bakheit
Ahmed H. Bakheit
EHEman Hassan
Eman Hassan
RHRashed N. Herqash
Rashed N. Herqash
FAFahad M. Almutairi
Fahad M. Almutairi

15 January 2020 in Royal Society Open Science
Verified
Journal Article
Open access
AAAbdulrahman Almehizia
Abdulrahman Almehizia
HAHaitham AlRabiah
Haitham AlRabiah
ABAhmed H. Bakheit
Ahmed H. Bakheit
EHEman Hassan
Eman Hassan
RHRASHED HERQASH
RASHED HERQASH
AAAli Abdelhameed
Ali Abdelhameed
The interactions of novel anti-cancer therapeutic agents with the different plasma and tissue components, specifically serum albumins, have lately gained considerable attention due to the significant influence of such interactions on the pharmacokinetics and/or -dynamics of this important class of therapeutics. Nazartinib (EGF 816; NAZ) is a new anti-cancer candidate proposed as a third-generation epidermal growth factor receptor tyrosine kinase inhibitor that is being developed and clinically tested for the management of non-small cell lung cancer. The current study aimed to characterize the interaction between NAZ and human serum albumin (HSA) using experimental and theoretical approaches. Experimental results of fluorescence quenching of HSA induced by NAZ revealed the development of a statically formed complex between NAZ and HSA. Interpretation of the observed fluorescence data using Stern–Volmer, Lineweaver–Burk and double-log formulae resulted in binding constants for HSA-NAZ complex in the range of (2.34–2.81) × 104M–1over the studied temperatures. These computed values were further used to elucidate thermodynamic attributes of the interaction, which showed that NAZ spontaneously binds to HSA with a postulated electrostatic force-driven interaction. This was further verified by theoretical examination of the NAZ docking on the HSA surface that revealed an HSA-NAZ complex where NAZ is bound to HSA Sudlow site I driven by hydrogen bonding in addition to electrostatic forces in the form of pi-H bond. The HSA binding pocket for NAZ was shown to encompass ARG 257, ARG 222, LYS 199 and GLU 292 with a total binding energy of −25.59 kJ mol–1.

15 May 2022 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
DYDalia G. Yasien
Dalia G. Yasien
EHEman Hassan
Eman Hassan
HMHanan A. Mohamed
Hanan A. Mohamed
Introduction: This study aimed to evaluate the phonatory function of recovered COVID-19 survivors. The universal outbreak of COVID-19 led to the occurrence of otolaryngological manifestations that raised concerns about the assessment of the phonatory function in recovering patients. Methods: This is a prospective, cross-sectional, case-controlled study carried out on 364 laboratory-confirmed non-critical COVID-19 survivors and 100 as healthy controls. The study participants were classified into two groups according to the disease severity. Group1 comprised 212 survivors who recovered from pneumonia and group 2 was made up of 152 survivors of severe pneumonia. All patients were subjected to an auditory perceptual assessment of the voice (APA) and Maximum Phonation Time (MPT) measurements. Results: Phonasthenic manifestations were significantly more frequent in COVID-19 survivors than in controls (P < 0.000) with a higher percentage recorded among severe pneumonia survivors (87.5%) than among pneumonia survivors (60.8%) with a P value of < 0.01. Dysphonia and excessively soft loudness were significantly more common among survivors than among controls (P < 0.002 and P < 0.000, respectively) with no significant difference between the patient groups. The MPT was significantly shorter among survivors than among controls (P < 0.000). The mean MPT was 15.97 s in the control group, 10.72 s in the pneumonia group, and 8.88 s in the severe pneumonia group, with the differences between the groups being statistically significant (P < 0.000), suggesting a higher impairment of lung volume and phonatory function in severe cases. Conclusions: Phonasthenia, dysphonia, and decreased MPT could be otolaryngological manifestations of COVID-19. Laryngeal function assessment should be considered in COVID-19 survivors.

26 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HAHany H. Arab
Hany H. Arab
AEAhmed Hamdy Eid
Ahmed Hamdy Eid
SAShuruq E Alsufyani
Shuruq E Alsufyani
AAAhmed Ashour
Ahmed Ashour
AAAlwaleed M. Alnefaie
Alwaleed M. Alnefaie
AEAlzahraa Ahmed Elhemiely
Alzahraa Ahmed Elhemiely
Despite being an effective chemotherapeutic agent, the clinical use of doxorubicin (DOX) is limited by several organ toxicities including hepatic injury. Pentoxifylline (PTX) is a methylxanthine derivative with marked anti-inflammatory and anti-apoptotic features. It is unknown, however, whether PTX can mitigate DOX-evoked hepatotoxicity. This study aims to explore the potential hepatoprotective impact of PTX in DOX-induced hepatic injury and the underlying molecular mechanisms. Histopathology, immunohistochemistry, and ELISA were used to examine liver tissues. The current findings revealed that PTX administration to DOX-intoxicated rats mitigated the pathological manifestations of hepatic injury, reduced microscopical damage scores, and improved serum ALT and AST markers, revealing restored hepatic cellular integrity. These favorable effects were attributed to PTX’s ability to mitigate inflammation by reducing hepatic IL-1β and TNF-α levels and suppressing the pro-inflammatory HMGB1/TLR4/NF-κB axis. Moreover, PTX curtailed the hepatic apoptotic abnormalities by suppressing caspase 3 activity and lowering the Bax/Bcl-2 ratio. In tandem, PTX improved the defective autophagy events by lowering hepatic SQSTM-1/p62 accumulation and enhancing the AMPK/mTOR pathway, favoring autophagy and hepatic cell preservation. Together, for the first time, our findings demonstrate the ameliorative effect of PTX against DOX-evoked hepatotoxicity by dampening the hepatic HMGB1/TLR4/NF-κB pro-inflammatory axis and augmenting hepatic AMPK/mTOR-driven autophagy. Thus, PTX could be utilized as an adjunct agent with DOX regimens to mitigate DOX-induced hepatic injury.